|
|
|
| Analysis of Drug Resistance and Related Drug Resistance Genotyping of Pseudomonas Aeruginosa |
| MA Ai-kuang, GAO Hua-li, WANG Min, et al |
| Clinical Laboratory, Shanghai Electric Power Hospital, Shanghai, 200050, China |
|
|
|
|
Abstract 【Objective】 To analyze the drug resistance and related drug resistance genotypes of Pseudomonas aeruginosa (PA). 【Methods 】 A total of 270 PA strains isolated from the laboratory department of Shanghai Electric Power Hospital were collected, the sensitivity of PA to 15 commonly used antibiotics was analyzed, and the expression of mexxy and mexab resistance genes was detected by RT-PCR. 【Results】The elderly aged 60 and above were most infected with Pseudomonas aeruginosa, 221 people, accounting for 81.86%, followed by 37 cases aged 30 ~ 60, accounting for 13.70%, and 12 cases aged 30 and below, accounting for 4.44%. The main source of PA was sputum, the detection rate was 47.04%, followed by urine (26.67%), wound (11.85%) and pharyngeal swab (11.85%). PA is mainly distributed in respiratory medicine, urology and neurology, of which 81 are most widely distributed in respiratory medicine, accounting for 30.00%. The resistance rates of PA to antibiotics from high to low were ticarcillin/clavulanic acid (24.07%), ciprofloxacin (23.70%), levofloxacin (22.96%), piperacillin (22.59%), ceftazidime (21.86%), imipenem (19.26%), aztreonam (19.26%), meropenem (18.52%), gentamicin (15.93%), tobramycin (15.56%) and cefepime (11.11%) , Cefoperazone/sulbactam (11.11%), piperacillin/tazobactam (10.37%), amikacin (8.15%) and polymyxin B (0.00%). Mexxy was expressed in 30% of PA strains, mexab was expressed in 42% of strains, and 16% of them were co expressed.【Conclusion】The elderly aged 60 and above in respiratory department ward are most vulnerable to PA infection. Overexpression of mexxy and mexab in active efflux system is one of the mechanisms of PA multidrug resistance.
|
|
Received: 23 July 2021
|
|
|
|
|
|
[1] MIELKO KA, JABLOńSKI SJ, MILCZEWSKA J, et al.Lukasz metabolomic studies of pseudomonas aeruginosa[J].World J Microbiol Biotechnol,2019,35(11):178.
[2] PANG Z, RAUDONIS R, GLICK BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies[J].Biotechnol Adv,2019,37(1):177-192.
[3] 黄勋,邓子德,倪语星,等.多重耐药菌医院感染预防与控制中国专家共识[J].中国感染控制杂志,2015,(1):1-9.
[4] 李耘,吕媛,郑波,等.中国细菌耐药监测研究2015-2016革兰氏阴性菌监测报告[J].中国临床药理学杂志,2017,33(23):2521-2542.
[5] WANG S, HUANG Z, WAN Q, et al. Comparative genomic and metabolomic analyses of two pseudomonas aeruginosa strains with different antifungal activities[J].Front Microbiol,2020,31(11):1841.
[6] HORCAJADA JP, MONTERO M, OLIVER A, et al. Epidemiology and Treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections[J].Clin Microbiol Rev,2019,32(4):231-239.
[7] 张静,陈泽涛,刘永贤.老年患者感染铜绿假单胞菌的相关因素及耐药情况分析[J].实用心脑肺血管病杂志,2018,26(5):85-87.
[8] 金淑娟.铜绿假单胞菌感染的抗菌药物治疗研究进展[J].儿科药学杂志,2018,24(1):54-57.
[9] FRANCOIS B, LUYT CE, STOVER CK, et al. New strategies targeting virulence factors of staphylococcus aureus and pseudomonas aeruginosa[J].Semin Respir Crit Care Med,2017,38(3):346-358.
[10] 王明贵.广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制:中国专家共识[J].中国感染与化疗杂志,2017,17(1):82-93.
[11] 吴婷婷,芮志莲,徐敏, 等.铜绿假单胞菌亚胺培南异质性耐药的机制[J].江苏大学学报(医学版),2018,28(4):297-301.
[12] 鞠晓红,王月华,孙艳美.铜绿假单胞菌MexXY外排泵调控机制研究进展[J].中国抗生素杂志,2019,44(1):40-46. |
|
|
|
2021, Vol. 38 
